Economics in getting a compound approved and commercialized are evolving. Drug companies have reduced budgets that historically funded vast R&D teams. Innovators are chasing tight investment dollars. The two camps are increasingly collaborating.

There is a self-selection factor rewarding start-ups — they can’t attract funding or licensing deals unless they’ve protected their intellectual property, showed …